Zydus Lifesciences Ltd. announced a significant regulatory milestone as Amplitude Surgical, a wholly owned subsidiary of Zydus MedTech France SAS, received CE mark approval for its proprietary robotic surgical system, Andy. The certification confirms the system’s compliance with European safety, performance, and quality standards, marking a major advancement in orthopaedic innovation.
Andy has been developed using Amplitude’s proprietary navigation platform, Amplivision, and integrates navigation technology with robotic assistance. The system has been built through a strategic collaboration with eCential Robotics, enhancing its precision-driven capabilities in the operating room.
Commenting on the development, Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Ltd., said the approval underscores the company’s commitment to patient-centric, future-ready innovation. He congratulated the Amplitude R&D team for their dedication and scientific excellence in bringing the robotic platform to life.
Designed as a true surgical partner, Andy is a collaborative robot equipped to perform bone resections with high precision and reliability. The system aims to improve surgical accuracy and ensure optimal alignment while minimizing tissue trauma. Its advanced capabilities are intended to deliver smaller incisions, reduced pain, faster recovery, fewer complications, and improved long-term implant performance for patients undergoing knee procedures. Hospitals are also expected to benefit from shortened recovery timelines and greater procedural consistency.
Earlier this year, Zydus MedTech strengthened its global presence through the strategic acquisition of Amplitude Surgical, a leading European MedTech company specializing in lower-limb orthopaedic technologies. The acquisition aligns with Zydus MedTech’s vision of delivering advanced, patient-focused solutions backed by research-driven design and precision engineering.
